New once-a-week drug could be part of weekly oral treatment
High blood pressure less common in people with HIV in Africa
European AIDS Treatment Group documents the impact of COVID on HIV services throughout Europe
Long-acting injectables work without oral lead-in period
Islatravir plus doravirine remains effective at 96 weeks
Promising results for programme to reduce sleep disturbance in people with HIV
Weight gain after switch to an integrase inhibitor does not boost 'bad fat'
Injectable HIV therapy should save money if adherence is better than to oral therapies
Weight gain on HIV treatment: what is normal, and what is harmful?
